Table 1. IC90 (μg/mL) and IC50 data for pyrrolocin B, PYRC and EQI.
| IC90 (μg/mL) | IC50 (μg/mL) | |||||
|---|---|---|---|---|---|---|
| S. aureus (ATCC 12600) | Methicillin-resistant S. aureus (ATCC 43300) | Clindamycin and Doxycycline-resistant S. aureus (CDC-568) | Vancomycin-resistant E. faecalis (ATCC 51229) | E. coli (ATCC 23724) | CEM-TART (1A2) | |
| pyrrolocin B | 16 | 16 | 16 | >32 | nt | <32 |
| pyrrolocin C | 1 | 1 | 0.5 | 2 | >128 | 8.841 |
| equisetin | 1 | 1 | 1 | 2 | >128 | 9.692 |
| polymyxin B | nt | nt | nt | nt | 0.5 | nt |
| polymyxin B nonapeptide | nt | nt | nt | nt | >64 | nt |
IC90’s determined as concentration required for > 90% inhibition, each determination performed at least twice, in quadruplicate. CEMTART (1A2) is a CCRF-CEM T lymphoblastic leukemia cell line derivative [11]. nt is not tested. IC50 experiment repeated twice, each concentration performed in triplicate.